← SynDRA
ELACRIDAR
SynDRA canonical compound SYN0007497 — structure-anchored drug synonym record
| Clinical phase | Phase 1 |
|---|
| Primary target(s) | ABCB1 |
|---|
| Mechanism of action | P-glycoprotein inhibitor |
|---|
All known targets
Mechanisms of action (all sources)
- P-glycoprotein inhibitor
- ABCB1 INHIBITOR
- ABCG2 INHIBITOR
- P glycoprotein inhibitor
- ABCB1 MODULATOR
- ABCB4 MODULATOR
Bioactivity evidence (ChEMBL activities table — not curator-asserted)
- ABCC1
- ABCC2
- HDAC6
- SLCO1B1
- SLCO1B3
- SLCO2B1
- YES1
Screening evidence (raw PubChem HTS — uncurated, known false-positive rate)
- 5HT2A
- HNMT
- SMAD3
- SMAD2
- RARA
- PRGR
- PNMT
- NTMT1
- NTM1A
- NR1I2
- NNMT
- KCNH2
- IFNG
- GNMT
- ACM1
- GLI3
- GAMT
- ESRRA
- ESR2
- CP3A4
- CP2D6
- CP2CJ
- CP2C9
- CP1A2
- COMT
- ANDR
- TSHR
Cross-references
Synonyms
- GF 120918
- LY-335979
- LY335979
- Zosuquidar HCl
- Zosuquidar Trihydrochloride
- Zosuquidar (TN)
- Zosuquidar trihydrochloride (USAN)
- RS-33295-198
- Zosuquidar trihydrochloride, RS-33295-198, LY335979
- (R)-4-((1aR,6R,10bS)-1,2-Difluoro-1,1a,6,10b-tetrahydrodibenzo(a,e)cyclopropa(c)cycloheptan-6-yl)-alpha-((5-quinoloyloxy)methyl)-1-piperazineethanol, trihydrochloride
- Elacridar hydrochloride
- Elacridar HCl
- Elacridar (hydrochloride)
- GF-120918A
- UNII-NX2BHH1A5B
- NX2BHH1A5B
- Elacridar hydrochloride [USAN]
- Elacridar hydrochloride (USAN)
- AC1Q3EOG
- AC1L55DX
- C34H34ClN3O5
- SCHEMBL15847793
- CHEMBL2074730
- AOB5938
- MolPort-023-332-877
- BCP14056
- 7066AA
- AKOS016005297
- CS-1113
- ACN-041487
- 4CA-0489
- HY-50880
- AC-30266
- FT-0696337
- W-5457
- D03968
- N-[4-[2-(3,4-Dihydro-6,7-dimethoxy-2(1H)-isoquinolinyl)ethyl]phenyl]-9,10-dihydro-5-methoxy-9-oxo-4-acridinecarboxamide hydro
Look up ELACRIDAR in the interactive SynDRA portal →